Get the Stockscreener App
18.12
0.93%
-0.17
After Hours:
19.02
0.90
+4.97%
Bioage Labs Inc stock is traded at $18.12, with a volume of 169.79K.
It is down -0.93% in the last 24 hours and down -24.06% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
See More
Previous Close:
$18.29
Open:
$19.5
24h Volume:
169.79K
Relative Volume:
1.05
Market Cap:
$649.58M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-20.07%
1M Performance:
-24.06%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$18.00
$19.89
1-Week Range:
$18.00
$22.87
52-Week Range:
$18.00
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
1445A SOUTH 50TH STREET, RICHMOND
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| BIOA | 18.12 | 649.58M | 0 | 0 | 0 | 0.00 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Bioage Labs Inc Stock (BIOA) Latest News
BioAge Labs Reports Strong Q3 2024 Achievements - Yahoo Finance
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs Reports Q3 Loss, Secures $334.5M Cash Runway Through 2029 After IPO | BIOA Stock News - StockTitan
BioArctic AB Sets Q3 2024 Earnings Call for November 14: Key Details Inside | BIOA Stock News - StockTitan
BioAge Labs, Inc. to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - Marketscreener.com
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 - GlobeNewswire
BioAge Labs to Present at Jefferies London Healthcare Conference - GlobeNewswire
Citi sets BioAge Labs Buy stock rating on obesity drug potential - Investing.com
BioAge Labs initiated with an Overweight at Morgan Stanley - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship - MSN
Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship (NASDAQ:BIOA) - Seeking Alpha
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up - Investing.com Australia
Wall Street analysts initiate coverage of BioAge Labs By Investing.com - Investing.com Canada
BioAge Labs stock initiated at buy, key obesity trial data expected by 2025 – Jefferies - Investing.com Canada
Morgan Stanley sets BioAge stock at Overweight rating, cites Lilly tie-up By Investing.com - Investing.com South Africa
Prediction: These 2 Stocks Could Soar in 2025 - Yahoo Finance
Stocks To Watch: BioAge Labs Sees Relative Strength Rating Jump To 94 - Investor's Business Daily
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock - Yahoo! Voices
RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc - Yahoo Finance
BioAge Labs’ $238 Million Upsized Initial Public Offering - Global Legal Chronicle
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October - MSN
Bioage Labs director acquires $4.3m in common stock By Investing.com - Investing.com UK
Bioage Labs director acquires $4.3m in common stock - Investing.com
This IPO Biotech Stock Could Be the Next Eli Lilly - The Motley Fool
Cormorant Asset Management buys $8.1m in BioAge Labs stock - Investing.com India
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - The Manila Times
BioAge Labs Announces Closing of Initial Public Offering, - GlobeNewswire
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement - ForexTV.com
Cormorant Asset Management buys $8.1m in BioAge Labs stock By Investing.com - Investing.com South Africa
Fenwick Represents BioAge Labs in $238 Million Upsized Initial Public Offering and Concurrent Private Placement - Fenwick & West LLP
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival (NASDAQ:BIOA) - Seeking Alpha
BioAge Labs director Enright buys $7.2 million in stock - Investing.com India
Finance Watch: BioAge Raises $198m In 20th Biopharma IPO Of 2024 - Scrip
Wave financing, BioAge IPO help biotech end September strong - BioCentury
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock - Investing.com Australia
BioAge Labs director Pande Vijay Satyanand buys $16.2m in stock By Investing.com - Investing.com South Africa
BioAge Labs director Enright buys $7.2 million in stock By Investing.com - Investing.com Australia
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.79%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):